当前位置:
X-MOL 学术
›
JAMA Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Advocating for Demonstration of Disease Modification-Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?
JAMA Neurology ( IF 20.4 ) Pub Date : 2023-04-24 , DOI: 10.1001/jamaneurol.2023.0815 Vincent Planche 1, 2 , Nicolas Villain 3, 4
JAMA Neurology ( IF 20.4 ) Pub Date : 2023-04-24 , DOI: 10.1001/jamaneurol.2023.0815 Vincent Planche 1, 2 , Nicolas Villain 3, 4
Affiliation
This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.
中文翻译:
提倡证明疾病改良——我们是否错误地对待早期阿尔茨海默病的临床试验?
该观点讨论了延迟启动设计和下游生物标志物分析的临床试验的好处,以检查抗髓系免疫疗法是否改变早期阿尔茨海默病的病程。
更新日期:2023-04-24
中文翻译:
提倡证明疾病改良——我们是否错误地对待早期阿尔茨海默病的临床试验?
该观点讨论了延迟启动设计和下游生物标志物分析的临床试验的好处,以检查抗髓系免疫疗法是否改变早期阿尔茨海默病的病程。